INVO BioScience Inc (INVO) Quote

sorry to hear that

Ive had a rough couple years myself

I guess I enjoy chasing since year 2000 ... anyway Ibrx I will get in first before FDA news Tuesday.. . don't have to chase

how is it you are always posting claiming you chased and bought tops?

Yeah glad we sold, thats about it for this thing, 1 day wonders make filthy amounts of money $$$$$$

$INVO nasty late day 8-K lowering warrant prices from 2.85 to 1.20 lol how is this legal?— madaz (@madaznfootballr) April 17, 2024

Thank you!

Mass profit on the quarter and a 2 million float..... an undiscovered gem just got discovered.

See press release after hours yesterday

Getting pushed

+312.50% What is going on here?

Up $1.25 premarket wish I caught that ride

Up large AH

Still some optimism in this play?

They filed S-4. Cheers bud. Stay positive Corvette. Be well. Rising tide. .

Was a glimmer of hope for awhile,I forgot about this for couple weeks now,maybe my brain just doesn’t want to see it since I am in over $2 smh

Remain positive Corvette. All will work out. We will get there eventually. I don’t see any victories until window opens up. I was hoping that they would devalue the hell out of this deal first then consummate and build it up from bottom. Sadly I don’t think that’s going to happen. I think the END consumer is in control and will most likely run this out until it’s ready. I still remain positive hoping that they choose my desired path. Hula Hula Cuckoo Penny

Remain positive Corvette. All will work out. We will get there eventually. I don’t see any victories until window opens up. I was hoping that they would devalue the hell out of this deal first then consummate and build it up from bottom. Sadly I don’t think that’s going to happen. I think the END consumer is in control and will most likely run this out until it’s ready. I still remain positive hoping that they choose my desired path. Hula Hula Cuckoo Penny

Don’t think anything is completed until enough consideration has been given to satisfy terms. They are spreading the love over a few months. Votes are locked in thanks to change in quorum minimum. Don’t need much to achieve change of control. lol. I believe termination date has been extended to April 30th. That’s good right. Nothing good reported yet Corvette. Have a lovely day. Hula Hula Cuckoo Penny

Nhod and power hour,could be gapper tomorrow

Chart looking good again

Been waiting on this awhile,3 different platforms all loaded up,$23k buy,ohhh my,big orders now and demand rising,no twit chatter yet,looking forward to big follower numbers on this one

Merger complete?macd heading up,first time in 30 days

I am always open to other ideas folk. I see Satellos / Naya still very involved in this collaboration between Astra and Immune Pharmaceuticals and Cytovia Tx. Ricky dink Invo is a means to an end for Naya.

If Naya recaps as I said it will and Invo terminates, Dissolves and deregisters ext…….. then Naya could be in the line of sight of ESHA. I don’t believe this will be the case. INVO is a nothing company. Naya is a nothing company. They suit each other just fine. They still have to bring in Satellos which could lift the combined company up a notch. Cytovia however remains private and it will need to be financed and an entrance to the circus tent. This could be done, and in my opinion, will be be done through ESHA. At that point Cytovia and ESHA will terminate, dissolve and same shit over again. It’s easier for Astra to absorb a private company and do future exchange in that scenario. If you see anything wrong in what I’m saying, please point out where I could be wrong, Hula Hula Cuckoo Penny

Merry Christmas.

I’m not considering any financing. This merger will not complete. Recap plan in action. You are the one wanting to do financing. Good luck with that. I am Canadian. I don’t do business in the US. So enjoy your thoughts about Naya. None of it will come true. Hula Hula Cuckoo Penny

Yes. They extended into next year. Same routine as before. Soon we will see termination, de-registration, dissolving and then on to the next couple mergers. As I keep saying. Nothing will be happening until 2025. Hula Hula Cuckoo Penny

Merger news today sunshine!!

I am still in,merger news was this morning,haven’t had time to read details yet

I don't think Naya should be counted out as a merger candidate with that spac in the future. If it is, so be it. Also, if you're considering financing in the future -> Wells Fargo is a good one.

Are we still thinking this will run soon?

Naya won’t be merging with ESHA. Cytovia will be the player in that scenario. Naya wishes it was the receiver. Rising Tide

Have a great one all you smart traders. Have a Merry Christmas. Hula Hula Cuckoo Penny

This merger 81vette is simply an add-on to the build and buy strategy that Astra Zeneca is working on. Do some due diligence and take a look at Satellos and SPAC ESHA. These companies have strong potential to be future merger candidates for Naya. Satellos is running cheap, and the shares for insiders are locked up in escrow for 36 months. The end date is right around date that Naya is to complete first merger. There is a much bigger picture here that involves a collaboration with Cytovia Tx, Immune Pharmaceuticals and Astra Zeneca. Another great company thats connected in this universe is Cellectis. They are the ones doing cell editing using their Talen tech for Cytovia products. Im thinking all companies share a purpose and will eventually be absorbed by Astra. Enjoy your Christmas season and keep enjoying the open road. Spread your love here and be rewarded. Be well. Hula Hula Cuckoo Penny

Getting more eyes on it,I haven’t sold any yet

Holding tight,patients is easy here,chart not broken,tic tock

Earnings out. = INVO Reports Record Third Quarter 2023 Financial Results
Company Expects to Host Conference Call Shortly After November 20, 2023 Following the Progress of Certain Closing Conditions Pertaining to the Announced Merger Agreement with NAYA Biosciences

SARASOTA, Fla., Nov. 13, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced financial results for the third quarter ended September 30, 2023 and provided a business update.


Q3 2023 Financial Highlights (all metrics compared to Q3 2022 unless otherwise noted)

Revenues of $974,894 increased 314% compared to $235,321.
Q3 2023 included only a partial quarter contribution from the recently acquired Wisconsin Fertility Institute (WFI). Pro forma revenue for Q3 2023, assuming a full quarter of WFI, would have been approximately $1.5 million.
Adjusted EBITDA was $(0.6) million compared to $(2.0) million. Pro forma adjusted EBITDA, assuming a full quarter contribution from WFI, would have been $(0.3) million and the Company is on a progression towards positive earnings and operating cashflows.
Clinic revenue increased 437% to $947,891, compared to $176,395. All reported clinic revenue is derived from the Company's INVO Centers in Atlanta, Georgia, and WFI (partial quarter) which are consolidated in the Company's financial statements.
Revenue from all clinics, inclusive of both those accounted for as consolidated and under the equity method, was $1,352,881, an increase of 169% compared to $502,993.
Total operating costs were approximately $1.9 million, a $0.9 million decrease compared to $2.8 million.
Net loss was $(1.2) million compared to $(2.5) million. Pro forma net loss, assuming a full quarter contribution from WFI, would have been $(1.0) million.
Exclusive of corporate overhead, the clinics generated positive net income in the period.
Recent Operational and Strategic Highlights

On August 10, 2023, INVO acquired WFI, a profitable Madison-based fertility center.
Implemented certain corporate expense reductions as part of go-forward plan to focus on its healthcare service strategy and a near-term path to profitability.
On October 23, 2023, INVO and NAYA Biosciences Inc., a company dedicated to increasing patient access to breakthrough treatments in oncology and regenerative medicine, jointly announced that they had entered into a definitive merger agreement for INVO to acquire NAYA Biosciences, Inc. ("NAYA") in an all-stock transaction.
Management Commentary

"The results of the quarter highlight the transformation of INVO into a growing, innovative healthcare services company leveraging our INVO Centers to drive IVC volume and obtain a greater share of the total fertility cycle revenue," commented Steve Shum, CEO of INVO. "When you look at the pro forma results for the quarter inclusive of a full quarter contribution from WFI our adjusted EBITDA would have been $(0.3) million, a significant improvement compared to ($2.0) million in the year ago quarter. Equally notable was the fact that our clinics, exclusive of our corporate costs, generated positive net income in the period. With the potential for continued growth from our family of INVO Centers, and more rationalized corporate operating expenses, achieving our stated goal of profitability in 2024 becomes increasingly visible. We look forward to maintaining our focus on driving growth and efficiencies in the business moving forward."

Definitive Merger Agreement

On October 23, 2023, INVO and NAYA, a company dedicated to increasing patient access to breakthrough treatments in oncology and regenerative medicine, jointly announced that they had entered into a definitive merger agreement (the "Merger") for INVO to acquire NAYA Biosciences in an all-stock transaction. Under the terms of the agreement, NAYA Biosciences' shareholders will receive 7.3333 shares of INVO for each share of NAYA Biosciences at closing, for a total of approximately 18,150,000 shares of INVO. Following the closing of the Merger, the combined company is expected to operate under the name "NAYA Biosciences".

As described in greater detail in the Company's SEC filings and press releases, the Merger remains subject to certain closing conditions including shareholder approval, an estimated $5 million or more (at NAYA's discretion) in interim private financing in INVO at a premium of INVO's market price at time of financing ("Interim PIPE"), and a private offering by the combined company at a target price of $5.00 per common share of INVO. At this time, there are no further updates on the satisfaction of the closing conditions.

"We are excited by the opportunity to merge INVO and NAYA and having the financial resources to advance both the fertility and newly acquired oncology operations," commented Shum. "We believe this combination provides the benefit of bringing our existing, revenue-generating operations from our fertility business with an ability to further grow these activities, along with the significant upside potential of innovative cancer therapeutics."

Financial Results

Only partial quarter results from WFI, which INVO acquired on August 10, 2023, are included in the results for the three months ended September 30, 2023. Where applicable, pro forma results are provided as if the acquisition closed on July 1, 2023 and therefore would have been included for the entire quarter.

Revenue for the three months ended September 30, 2023, was $974,894 compared to $235,321 for the three months ended September 30, 2023, an increase of 314%. Pro forma revenue for Q3 2023, assuming a full quarter of WFI, would have been $1,492,520, an increase of 534%.

Clinic revenue from the Company's consolidated INVO Centers was $947,891 during the third quarter of 2023, an increase of 437% compared to $176,395 for the three months ended September 30, 2022. Revenue from all INVO Centers combined was $1,352,881, an increase of 201% compared to the year-ago period.

Selling, general and administrative expenses for the three months ended September 30, 2023, were approximately $1.3 million compared to approximately $2.3 million for the three months ended September 30, 2022. The decrease of approximately $1.0 million, or approximately 46%, was primarily the result of approximately $1.1 million in decreased personnel expenses and approximately $0.2 million in decreased marketing expenses, and was partially offset by a $0.1 million increase in professional fees and a $0.1 million increase in operational expenses related to WFI.

R&D expenses were approximately $0.0 million and $0.2 million for the three months ended September 30, 2023, and September 30, 2022, respectively. The decrease is a result of the Company receiving FDA clearance in June 2023 for its 510(k) application.

Total operating costs were $1.9 million and $2. 8 million for the three months ended September 30, 2023, and September 30, 2022, respectively.

Net loss was $(1.2) million and $(2.5) million for the three months ended September 30, 2023, and September 30, 2022, respectively. Pro forma net loss, assuming a full quarter contribution from WFI, would have been approximately $(1.0) million.

Adjusted EBITDA (see Adjusted EBITDA Table) for the three months ended September 30, 2023, was $(0.6) million, compared to adjusted EBITDA of $(2.0) million for the quarter ended September 30, 2022. Pro forma adjusted EBITDA, assuming a full quarter contribution from WFI, would have been approximately $(0.3) million.

As of September 30, 2023, the Company had approximately $1.1 million in cash.

Use of Non-GAAP Measure

Adjusted EBITDA is a non-GAAP measure. This measure is not intended to be a substitute for those financial measures reported in accordance with GAAP. Adjusted EBITDA has been included because management believes that, when considered together with the GAAP figures, it provides meaningful information related to our operating performance and liquidity and can enhance an overall understanding of financial results and trends. Adjusted EBITDA may be calculated by us differently than other companies that disclose measures with the same or similar terms. See our attached financials for a reconciliation of this non-GAAP measure to the nearest GAAP measure.

Conference Call Details

INVO will announce details for a conference call in a future press release. The conference call is expected to be held after November 20, 2023, and following the progress of certain closing conditions pertaining to the Merger.

About INVO Bioscience

We are a healthcare services fertility company dedicated to expanding the assisted reproductive technology ("ART") marketplace by making fertility care accessible and inclusive to people around the world. Our commercialization strategy is focused on the opening of dedicated "INVO Centers" offering the INVOcell® and IVC procedure (with three centers in North America now operational), the acquisition of US-based, profitable in vitro fertilization ("IVF") clinics and the sale and distribution of our technology solution into existing fertility clinics. Our proprietary technology, INVOcell®, is a revolutionary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. This treatment solution is the world's first intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. This technique, designated as "IVC", provides patients a more natural, intimate, and more affordable experience in comparison to other ART treatments. We believe the IVC procedure can deliver comparable results at a fraction of the cost of traditional IVF and is a significantly more effective treatment than intrauterine insemination ("IUI"). For more information, please visit www.invobio.com.

Safe Harbor Statement

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results t

Your words made me jumped in where 4.5

Get what can it’s going to 4.50

Big dump-a-thon

Definitive merger with $5.00pps coming

Accumulation todaylooking good so far

Presentation today>”accelerating biotech value creation”supposed to be breakthrough treatments,change the world innovation could gain attention,we shall see if they let this 2.5m float run

ZERO BORROW,NOT OPTIONABLE,short fee 462%

ok I got to get away before I do something stupid and chase up here

its obviously a rocket play, but could halt tank any moment

hard to read up here

imo

better to just leave it alone

i did it again LOL sold 2.412 and it halts up 2.49

but feels so risky up here... hard to HOLD

7.20 to .50 how sick was that

what are you waiting for?

2.44 not high enuff for you?

LOL

I take it you didnt but many shares

easy to hold small lots harder to hold size and NOT take profit$

anyways G<L

Not much

DANG IT 2.44 SOLD 2.13 BUT HALTED DOWN AGAIN 2.17

FEELS FROTHY BUT ALSO FELT THAT WAY @ 1.80

I’m still holding